Laura Taraboanta is a digital medicine and clinical innovation leader currently serving as Digital & Imaging Project Lead within the Digital Medicine & Translational Imaging (DMTI) group at Pfizer. In this role, she leads the development and execution of digital measurement strategies across therapeutic programs, working with multidisciplinary teams to validate and implement novel digital endpoints that enhance clinical trials and drug development.
Laura brings more than a decade of experience at the intersection of healthcare, technology, and clinical research. She has led decentralized clinical trial initiatives, driven regulatory engagements in digital medicine, and built collaborations with leading pharmaceutical companies, academic institutions, and digital health innovators. Her work focuses on translating emerging technologies—including digital biomarkers, AI-enabled measurement tools, and software-based therapeutics—into scalable clinical solutions that improve patient outcomes and modernize evidence generation. Prior to Pfizer, she held leadership roles at Click Therapeutics and Woebot Health, contributing to pioneering digital medicine programs across CNS and cardiometabolic disease areas.
Laura holds advanced degrees in Biochemistry and Bioethics from Case Western Reserve University and earned her Master of Science in Innovation & Management from Tufts University.